Prevalence of Metabolic Syndrome in Patients With Schizophrenia in Korea

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01477918

Enrollment

1000

Registered

2011-11-23

Start date

2011-12-31

Completion date

Unknown

Last updated

2011-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Schizophrenia

Keywords

prevalence, Korea

Brief summary

The aim of this study is to examine the prevalence of the Metabolic syndrome(MetS) in Korean patients with schizophrenia. Primary objective: • To investigate the prevalence of the MetS in Korean patients with schizophrenia Secondary objectives: • To compare the prevalence of the MetS among 3 groups according to antipsychotics: typical antipsychotic monotherapy group, atypical antipsychotic monotherapy group, 2 or more antipsychotics group (polypharmacy)

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of schizophrenia according to DSM-IV-TR * Age between 18-65 years

Design outcomes

Primary

Measure	Time frame	Description
prevalence of metabolic syndrome (MetS)	—	MetS will be diagnosed according to NCEP ATP III with the Asian-Pacific abdominal obesity criterion (≥90 cm in men, ≥85 cm in women) 3 or more of the following criteria 1. fasting plasma glucose \>= 100 mg/dl or drug use to treat elevated glucose 2. serum triglyceride (TG) \>= 150 mg/dl or drug use to treat elevated TG 3. HDL cholesterol level \< 40mg /dl in males, \< 50 mg/dl in female or drug use to treat low HDL 4. Systolic BP \>=130 mmHg, diastolic BP \>=85 or drug use to treat hypertension 5. Abdominal obesity : above described

Countries

South Korea

Contacts

Primary ContactYeon-Ho Joo, Ph.D.

jooyh@amc.seoul.kr82-2-3010-3412

Outcome results